BREAKING: Rep. Tom Price Gets Senate Committee Vote Despite Boycott from Democrats | Healthcare Informatics Magazine | Health IT | Information Technology Skip to content Skip to navigation

BREAKING: Rep. Tom Price Gets Senate Committee Vote Despite Boycott from Democrats

February 1, 2017
by Rajiv Leventhal
| Reprints

Even without Democrats present, the Senate Finance Committee today advanced the nomination of U.S. Rep. Tom Price, M.D. (R-Ga.) to serve as Department of Health and Human Services (HHS) Secretary.

The move to vote on Price’s nomination with just Republicans present goes against committee rules, which calls for 13 members—including at least one Democrat—to be present for the vote. Yesterday, Democrats on the U.S. Senate Finance Committee boycotted the committee’s vote on Price’s nomination. As such, without a quorum on the Senate Finance committee, the vote was delayed. Democrats on the committee again stayed away from the hearing today, for a second straight day, but Republicans voted to suspend the rule that had required at least one Democrat to be present for business to be conducted, according to media reports.

Republican members of the committee, who were all present, approved Price 14-0, moving the vote to the full Senate. Following the vote, Chairman Orrin Hatch (R-Utah) issued the following statement: “We need decisive, solution-oriented leaders in the administration, particularly at Treasury and HHS.  As Congress navigates the minefields of tax reform, healthcare reform, and other vitally important matters, we need willing and competent partners to lead these crucial Executive Branch departments.  I believe these two nominees can and will provide the necessary leadership that will allow us to be successful in these many endeavors, and I look forward to their nominations being considered by the full Senate.” (Just like they did with Price, Republican Senate Finance Committee members similarly moved forward the nomination of Steven Mnuchin to head the Treasury Department, with the same 14-0 approval, also without Democratic presence). 

Rep. Tom Price, M.D.

Republicans on the committee were far from pleased with the boycott from Democrats. Hatch said yesterday, “This is one of the most alarming things I’ve seen in my 40 years in the U.S. Senate. They [Democrats] filed a list of demands just this morning. It’s not only ridiculous, it’s offensive.”

According to a Yahoo report, on Wednesday, “Committee aides said the panel had notified the Democrats a half-hour before Wednesday's proceedings. Hatch said he had obtained approval from the Senate parliamentarian for the move suspending the rule. 'We took some unprecedented action today due to some unprecedented obstruction on the part of our colleagues,'" said Hatch.

During Price’s two nomination hearings, first in the Senate HELP Committee and then in the Senate Finance Committee, Senate Democrats on those two committees repeatedly grilled Price regarding his investments in healthcare firms and his trading in healthcare stocks during his time in Congress. Among Price’s holdings are some in Innate Immunotherapeutics, Ltd., an Australian biomedical company in which another lawmaker, Rep. Chris Collins (R-N.Y.) is a major shareholder.

According to his financial disclosure statements, on Aug. 31 Price bought between $50,001 and $100,000 worth of stock the firm, as noted in an article in the online publication STAT. In Price’s first Senate hearing, Sen. Patty Murray (D-Wash.) strongly challenged Price’s explanations of how he came to invest in Innate Immunotherapeutics.

As reported by Healthcare Informatics at the time of the first hearing, “Indeed, throughout the hearing, Price was pressed by Democratic senators about the Innate Immunotherapeutics investment as well his purchase of shares in medical device manufacturer Zimmer Biomet last year. A CNN report noted that “Price bought between $1,001 to $15,000 worth of shares last March in Zimmer Biomet, and “less than a week after the transaction,” Price introduced legislation “that would have delayed until 2018 a Centers for Medicare and Medicaid Services (CMS) regulation that industry analysts warned would significantly hurt Zimmer Biomet financially once fully implemented.”

And, during the Senate Finance committee hearing last week, Price’s second Congressional hearing in as many weeks, Sen. Ron Wyden (D-Oregon) further questioned Price about healthcare stocks and said he saw a conflict while also contending that Price understated the value of his investments in Innate Immunotherapeutics. “It is hard to see this as anything but a conflict of interest and an abuse of position,” Wyden said.

Wyden tweeted this morning that Democrats want answers to Price’s stock trades that have been called into question.


Get the latest information on Health IT and attend other valuable sessions at this two-day Summit providing healthcare leaders with educational content, insightful debate and dialogue on the future of healthcare and technology.

Learn More